ACTRT1

Across TCGA pan-cancer cohorts, ACTRT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACTRT1 data layer compared with 13 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACTRT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACTRT1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where ACTRT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.284	0.760	.004	17	view →
LUAD	DFS	Median	All	0.583	0.938	.018	11	view →
CCRCC	DFS	Tertile	IV	0.961	0.174	.024	8	view →
GBM	DFS	Quartile	All	0.234	0.749	.010	5	view →
LSCC	OS	Quartile	All	0.502	1.000	.043	2	view →
HNSC	OS	Median	IV	0.902	0.606	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACTRT1–PDAC (DFS)

Open the PDAC breakdown →